Whole-genome sequencing exposes missed causes of young-onset dialysis
Young patients on dialysis often carry broad clinical labels such as diabetic kidney disease, nephrosclerosis, chronic glomerulonephritis, or kidney failure of unknown cause. In this Japanese multicenter preprint, integrated genomic review found a genetic or systemic explanation in a meaningful minority even after patients with clinically apparent polycystic kidney disease were removed from the analysis. The study focused on a group in whom the usual diagnostic shorthand can obscure inherited disease, especially when renal decline begins early and the phenotype is blurred by overlapping comorbidities.
Among 1,139 people receiving maintenance dialysis at participating facilities, 355 had started dialysis at age 50 years or younger. After excluding 17 with clinically apparent PKD, 108 of 338 eligible patients entered voluntary, nonrandom whole-genome sequencing. The sequencing strategy was broad: 465 nuclear candidate genes, mitochondrial DNA, and copy-number and structural variant analysis were all included. In that setting, diagnoses were identified in 10 of 108 participants, for an integrated diagnostic yield of 9.3%.
One sentence captures the practical implication: conventional labels missed a biologically diverse set of disorders.
Diagnostic yield held across common clinical labels
The reported diagnoses were not confined to a single nephrology niche. They appeared across diabetic kidney disease, nephrosclerosis, chronic glomerulonephritis, unknown-cause kidney failure, and other clinical categories. Seven diagnoses were renal and three were systemic or metabolic, which is important because kidney failure may be the endpoint of a broader inherited syndrome rather than an isolated renal process. In real bedside terms, a patient starting dialysis in middle age can look like a common CKD case while actually carrying a variant-driven disorder with implications for family counseling, extra-renal surveillance, and recurrence risk in relatives.
Nine of the ten diagnoses were supported by pathogenic or likely pathogenic variants, yielding an 8.3% P/LP-supported diagnostic rate. The remaining case was a phenotype-based clinical diagnosis of Dent disease associated with a CLCN5 variant of uncertain significance. The distinction between integrated diagnosis and strict variant classification matters here because phenotype, family history, and biochemical pattern can still point toward a monogenic disorder even when the variant evidence is incomplete.
A post hoc analysis removed three participants with low target coverage. After that adjustment, the integrated and P/LP-supported proportions were 9 of 105 and 8 of 105, respectively. Six exploratory findings were excluded from both diagnostic numerators. Those exclusions temper interpretation, but they do not erase the central signal: sequencing uncovered hidden disease in a cohort already filtered by clinical judgment.
Why young-onset kidney failure hides inherited disease
The pathophysiology behind this diagnostic overlap is straightforward. Kidney failure in younger adults is often the endpoint of several converging pathways: inherited tubulopathies, podocytopathies, metabolic disorders, mitochondrial disease, and structural kidney disease that never declared itself with a classic family pedigree. When a patient also has diabetes, hypertension, or nonspecific glomerular disease, the inherited contribution can be mislabeled as secondary or idiopathic. Whole-genome sequencing helps separate those layers by detecting variants that do not fit neatly into a standard CKD chart abstraction.
Several of the identified diagnoses were systemic or metabolic rather than purely renal. That pattern suggests the kidney failure may have been one organ manifestation of a wider disorder, and the renal diagnosis was only one piece of the biology. In clinical genetics, this is the difference between naming a final organ failure and identifying the upstream pathway that produced it.
Coverage gaps and enrollment bias limit what the negative results mean
The study design also places guardrails around the findings. Enrollment was voluntary and nonrandom, so the analyzed group may not represent all young-onset dialysis patients in the participating centers. Variable sequencing coverage introduced another layer of uncertainty, particularly for the negative results. A patient without an identified diagnosis may still have a causal variant that was not adequately captured, or a disorder outside the 465-gene candidate set.
The investigators also flagged Gitelman syndrome as a clinically manifest renal disorder, while its contribution to kidney failure remained uncertain. That careful wording is clinically important because not every genetically defined renal syndrome explains the dialysis endpoint in a simple one-to-one way. Some variants may contribute to chronic electrolyte or tubular abnormalities without being the sole cause of end-stage kidney disease.
One concrete bedside consequence follows: a negative genome in young-onset dialysis should not be treated as a full etiologic answer.
What nephrologists take from the sequencing signal
The study argues for a lower threshold to consider genomic reassessment in younger dialysis patients, even when a plausible acquired diagnosis already exists. A diagnosis of diabetic kidney disease or hypertensive nephrosclerosis does not exclude a monogenic contributor, and the yield in this cohort suggests that hidden inherited disease is common enough to matter in specialty practice. The broader clinical value goes beyond classification. A molecular diagnosis can influence cascade testing, family planning, transplant evaluation, and screening for nonrenal manifestations.
The work also shows why integrated review remains necessary instead of relying on variant interpretation alone. Some findings will be variant-confirmed and straightforward. Others will sit in a gray zone where phenotype, segregation, and biological plausibility carry the diagnostic weight. In young-onset dialysis, that gray zone is not a technical footnote; it is often where the real answer lives.
Because this is a preprint, the findings still need peer review and external replication. Nonrandom enrollment, the exclusion of patients with clinically apparent PKD, and variable target coverage all limit generalizability. Even so, the dataset makes a strong case that genomic reassessment can uncover renal and systemic disease hiding inside familiar dialysis labels, and that the absence of an obvious inherited history should not close the diagnostic workup too early.